Neurogene Inc. (NGNE)
Automate Your Wheel Strategy on NGNE
With Tiblio's Option Bot, you can configure your own wheel strategy including NGNE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NGNE
- Rev/Share 0.0441
- Book/Share 13.8975
- PB 1.5434
- Debt/Equity 0.0464
- CurrentRatio 21.0301
- ROIC -0.2939
- MktCap 305922045.0
- FreeCF/Share -3.3935
- PFCF -4.2936
- PE -5.5691
- Debt/Assets 0.043
- DivYield 0
- ROE -0.3616
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | NGNE | Craig Hallum | -- | Buy | -- | $50 | June 17, 2025 |
| Downgrade | NGNE | Robert W. Baird | Outperform | Neutral | -- | $24 | May 16, 2025 |
News
Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV
Published: May 16, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced an oral presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting describing a monitoring and treatment algorithm intended to reverse the rare, severe hyperinflammatory syndrome hemophagocytic lymphohistiocytosis (HLH) that has been associated with systemic e.
Read More
Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates
Published: May 09, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced first quarter 2025 financial results and highlighted recent corporate updates. “We have made significant progress in planning for our future registrational trial with NGN-401 gene therapy for Rett syndrome and expect to provide an update on our plans during the first half of this year,.
Read More
About Neurogene Inc. (NGNE)
- IPO Date 2014-03-07
- Website https://www.neurogene.com
- Industry Biotechnology
- CEO Rachel L. McMinn
- Employees 107